SSC
CATX icon

Spruce Street Capital’s Perspective Therapeutics CATX Stock Holding History

Spruce Street Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
3,693,931
+1,066,824
+41% +$4.03M 2.47% 12
2026
Q1 		$11M Buy
+2,627,107
New +$11.1M 2.63% 15

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Spruce Street Capital's CATX Position: Q2 2026 in Review

Spruce Street Capital increased its Perspective Therapeutics (CATX) stake by 41% in Q2 2026, buying an estimated $4.03M and bringing the position to 3,693,931 shares worth $12.6M. The position accounts for 2.47% of the portfolio, ranked #12.

Spruce Street Capital first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Spruce Street Capital held 3,693,931 shares of Perspective Therapeutics worth $12.6M as of Q2 2026.
  • Spruce Street Capital bought 1,066,824 Perspective Therapeutics shares in Q2 2026, an estimated $4.03M.
  • Perspective Therapeutics made up 2.47% of Spruce Street Capital's portfolio in Q2 2026, its #12 holding.
  • Spruce Street Capital first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.